Our top pick for
Hoth Therapeutics, Inc is a biotechnology business based in the US. Hoth Therapeutics shares (HOTH) are listed on the NASDAQ and all prices are listed in US Dollars. Hoth Therapeutics employs 2 staff and has a market cap (total outstanding shares value) of USD$22.3 million.
|Latest market close||USD$1.65|
|52-week range||USD$1.6 - USD$7.25|
|50-day moving average||USD$1.7136|
|200-day moving average||USD$2.2181|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.493|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-21.80%|
|1 month (2020-12-18)||-0.60%|
|3 months (2020-10-16)||-7.82%|
|6 months (2020-07-17)||-44.82%|
|1 year (2020-01-17)||-67.09%|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-126.6%|
|Return on equity TTM||-213.75%|
|Market capitalisation||USD$22.3 million|
TTM: trailing 12 months
There are currently 23,857 Hoth Therapeutics shares held short by investors – that's known as Hoth Therapeutics's "short interest". This figure is 101.5% up from 11,839 last month.
There are a few different ways that this level of interest in shorting Hoth Therapeutics shares can be evaluated.
Hoth Therapeutics's "short interest ratio" (SIR) is the quantity of Hoth Therapeutics shares currently shorted divided by the average quantity of Hoth Therapeutics shares traded daily (recently around 265077.77777778). Hoth Therapeutics's SIR currently stands at 0.09. In other words for every 100,000 Hoth Therapeutics shares traded daily on the market, roughly 90 shares are currently held short.
However Hoth Therapeutics's short interest can also be evaluated against the total number of Hoth Therapeutics shares, or, against the total number of tradable Hoth Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hoth Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Hoth Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0024% of the tradable shares (for every 100,000 tradable Hoth Therapeutics shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hoth Therapeutics.
Find out more about how you can short Hoth Therapeutics stock.
We're not expecting Hoth Therapeutics to pay a dividend over the next 12 months.
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.